Treating Advanced Breast Cancer After Progression on CDK4/6 Inhibitors [Video]

The combination of abemaciclib (Verzenio) plus fulvestrant (Faslodex) significantly improved progression-free survival (PFS) versus fulvestrant alone in patients with hormone receptor-positive/HER2-negative advanced breast cancer who had disease progression on a CDK4/6 inhibitor and endocrine therapy, according to phase III data presented at the American Society of Clinical Oncology (ASCO) annual meeting.

MedPage Today brought together three expert leaders in the field for a virtual roundtable discussion: Moderator Hope S. Rugo, MD, of the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, is joined by Joyce O’Shaughnessy, MD, of Baylor University Medical Center, Texas Oncology, in Dallas, and Sara Tolaney, MD, MPH, of Dana-Farber Cancer Institute in Boston. This second of four exclusive episodes focuses on the postMONARCH study.

Click here to watch the other videos from this ASCO roundtable series on breast cancer.

Following is a transcript of their remarks:

Rugo:We also saw another study that was really hotly awaited. Both of these …